Basaglar.
作者信息
Newsome Cheyenne
机构信息
Washington State University College of Pharmacy, Spokane, WA.
出版信息
Clin Diabetes. 2017 Jul;35(3):181. doi: 10.2337/cd017-0025.
Abstract
摘要
相似文献
1
Basaglar.百畅泽（胰岛素甘精注射液的商品名）
Clin Diabetes. 2017 Jul;35(3):181. doi: 10.2337/cd017-0025.
2
Basaglar, an Insulin 'Follow On,' Prepares To Do Battle With Lantus.基础胰岛素类似物Basaglar准备与来得时展开竞争。
Manag Care. 2017 Apr;26(4):12-14.
3
Basaglar: A Hypersensitivity Reaction.百畅泽：一种超敏反应。
Clin Diabetes. 2018 Apr;36(2):205-207. doi: 10.2337/cd17-0051.
4
Glargine U-100 (Basaglar®): A Follow-On Insulin.
Home Healthc Now. 2016 Jun;34(6):336-7. doi: 10.1097/NHH.0000000000000414.
5
Similar Efficacy and Safety of Basaglar and Lantus in Patients with Type 2 Diabetes in Age Groups (< 65 Years, ≥ 65 Years): A Post Hoc Analysis from the ELEMENT-2 Study.在2型糖尿病患者中（年龄组<65岁、≥65岁），Basaglar和来得时的疗效与安全性相似：来自ELEMENT-2研究的事后分析
Diabetes Ther. 2018 Apr;9(2):827-837. doi: 10.1007/s13300-018-0405-5. Epub 2018 Mar 14.
6
Another insulin glargine (Basaglar) for diabetes.
Med Lett Drugs Ther. 2017 Jan 2;59(1511):3-4.
7
Nonclinical pharmacology and toxicology of the first biosimilar insulin glargine drug product (BASAGLAR/ABASAGLAR) approved in the European Union.欧盟批准的首个生物类似药甘精胰岛素产品（BASAGLAR/ABASAGLAR）的非临床药理学与毒理学
Regul Toxicol Pharmacol. 2017 Aug;88:56-65. doi: 10.1016/j.yrtph.2017.05.013. Epub 2017 May 17.
8
Expanded table: some available insulins for type 2 diabetes.
Med Lett Drugs Ther. 2019 May 6;61(1571):e73-e77.
9
Insulins for type 2 diabetes.用于2型糖尿病的胰岛素。
Med Lett Drugs Ther. 2019 May 6;61(1571):65-68.
10
Insulin: Making Sense of Current Options.胰岛素：当前选择解析。
Endocrinol Metab Clin North Am. 2016 Dec;45(4):845-874. doi: 10.1016/j.ecl.2016.06.009.
引用本文的文献
1
State Substitution Laws and Uptake of an Interchangeable Insulin Biosimilar.州替代法与可互换胰岛素生物类似药的使用情况
JAMA Health Forum. 2025 Apr 4;6(4):e250406. doi: 10.1001/jamahealthforum.2025.0406.
2
Estimated Changes in Insulin Prices and Discounts After Entry of New Insulin Products, 2012-2019.2012-2019 年新胰岛素产品上市后胰岛素价格和折扣的估计变化。
JAMA Health Forum. 2023 Jun 2;4(6):e231430. doi: 10.1001/jamahealthforum.2023.1430.
3
Real-World Impact of Switching From Insulin Glargine (Lantus) to Basaglar and Potential Cost Saving in a Large Public Healthcare System in Saudi Arabia.在沙特阿拉伯的大型公共医疗体系中，从甘精胰岛素（来得时）切换到贝塔西拉（Basaglar）的实际影响和潜在成本节约。
Front Public Health. 2022 Jun 13;10:852721. doi: 10.3389/fpubh.2022.852721. eCollection 2022.
本文引用的文献
1
BIOSIMILARS AND NEW INSULIN VERSIONS.生物类似药与新型胰岛素制剂
Endocr Pract. 2015 Dec;21(12):1387-94. doi: 10.4158/EP14595.RA. Epub 2015 Sep 4.
2
Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study.在一项随机对照试验中，LY2963016 胰岛素甘精与胰岛素甘精（来得时）治疗 1 型糖尿病患者的疗效和安全性比较：ELEMENT 1 研究。
Diabetes Obes Metab. 2015 Aug;17(8):726-33. doi: 10.1111/dom.12496. Epub 2015 Jun 23.
3
Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study).LY2963016 胰岛素甘精和胰岛素甘精（来得时®）在初治或既往使用胰岛素甘精的 2 型糖尿病患者中的疗效和安全性相似：一项随机、双盲对照试验（ELEMENT 2 研究）。
Diabetes Obes Metab. 2015 Aug;17(8):734-41. doi: 10.1111/dom.12482. Epub 2015 May 31.
Zotero 插件